A major international effort to rename polycystic ovary syndrome (PCOS) is drawing attention to one of the most common — and most widely misunderstood — hormonal conditions affecting women worldwide, and what decades of medical language may have obscured in the process.
As of this week, the condition is now being reclassified as polyendocrine metabolic ovarian syndrome (PMOS), following a global consensus process led by endocrinology experts and patient advocacy organizations, including the Endocrine Society. The change reflects a broader scientific understanding of the condition as a multisystem disorder that affects metabolic, hormonal, reproductive and mental health — not simply a condition defined by ovarian cysts.
For years, experts say, the name “polycystic ovary syndrome” contributed to confusion in both clinical and public understanding. Many patients were told they did not have PCOS if cysts were not visible on ultrasound, despite the fact that ovarian cysts are not required for diagnosis. The Cleveland Clinic notes that symptoms instead vary widely and can include irregular menstrual cycles, elevated androgen levels, acne, hair growth or loss, infertility and metabolic complications.
Researchers involved in the renaming effort argue that this misunderstanding has contributed to delayed diagnosis and fragmented care. Some estimates suggest that a significant share of patients remain undiagnosed or misdiagnosed for years, often cycling through providers before receiving a clear explanation for their symptoms.
Under the new term PMOS, clinicians aim to emphasize the condition’s metabolic dimension, including its links to insulin resistance, type 2 diabetes risk and cardiovascular health. Advocates say that reframing the condition may also reduce stigma and help patients receive earlier, more comprehensive treatment.
PMOS affects roughly 1 in 8 women globally, making it one of the most common endocrine disorders in reproductive-aged women.
Start your day with essential news from Salon.
Sign up for our free morning newsletter, Crash Course.
Still, experts caution that a name change alone will not resolve long-standing gaps in research funding, clinical training or access to care. Diagnostic criteria remain unchanged for now, meaning the impact of the reclassification will depend heavily on whether medical practice follows the science.
Even so, patient advocates involved in the process describe the shift as a long-overdue correction — one that attempts to align medical language more closely with lived experience, and to ensure that symptoms long dismissed or misinterpreted are recognized sooner in the future.
